LTR Pharma (ASX:LTP) said its SPONTAN nasal spray product will be available through TerryWhite Chemmart's pharmacy network in Australia under its earlier distribution agreement with Symbion, according to a Tuesday Australian bourse filing.
TerryWhite Chemmart is a subsidiary of EBOS Group (ASX:EBO, NZE:EBO) alongside Symbion, the filing said.
LTR Pharma developed new commercial packaging for the SPONTAN intranasal spray, designed for pharmacy distribution and incorporating Therapeutic Goods Administration-compliant labeling, patient information materials, and pharmacy-standard barcodes.
The expanded pharmacy rollout will allow the firm to gather real-world data on SPONTAN usage to support its regulatory strategy and preparations for a full commercial launch following regulatory approval in Australia.
Its shares jumped over 38% in recent trading on Tuesday.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。